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7,8-Dihydroxyflavone (7,8-DHF), a tyrosine kinase B agonist that mimics the
neuroprotective properties of brain-derived neurotrophic factor, which can not efficiently
deliver into the brain, has been reported to be useful in ameliorating cognitive impairment
in many diseases. Researches have indicated that apolipoprotein E-knockout (ApoE-
KO) mouse was associated with cognitive alteration via various mechanisms. Our
present study investigated the possible mechanisms of cognitive impairment of ApoE-
KO mouse fed with western type diet and the protective effects of 7,8-DHF in improving
spatial learning and memory in ApoE-KO mouse. Five-weeks-old ApoE-KO mice and
C57BL/6 mice were chronically treated with 7,8-DHF (with a dosage of 5 mg/kg) or
vehicles orally for 25 weeks, and then subjected to Morris water maze at the age of
30 weeks to evaluate the cognitive performances. Afterward, histology analysis and
western blotting were performed. Spatial learning and memory deficits were observed
in ApoE-KO mice, which were consistent with higher expression of active-asparaginyl
endopeptidase (active-AEP) as well as AEP-derived truncated tau N368 compared
with normal group. In addition to that, long-term treatment of 7,8-DHF dramatically
ameliorated cognitive decline in ApoE-KO mice, accompanied by the activation in
phosphorylated protein kinase B (Akt)/glycogen synthase kinase-3β (GSK-3β) pathway
and down-regulated expression of tau S396 and PHF-tau (phosphorylated tau at
ser396 and ser404 epitope). These findings suggested that cognitive impairment of
ApoE-KO mouse might associate with tau pathology and 7,8-DHF could activate AKT
and then phosphorylate its downstream molecule to inhibit expression of abnormal
tau, meanwhile, 7,8-DHF could reduce the expression of active-AEP and then inhibit
production of truncated tau N368.
Keywords: 7,8-dihydroxyflavone, ApoE knockout, cognitive impairment, neuroprotective, tau pathology,
asparaginyl endopeptidase, protein kinase B, glycogen synthase kinase-3β
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INTRODUCTION
Apolipoprotein E (ApoE) has been closely linked to AD-
associated pathology, like neurofibrillary tangles and amyloid
plaques. Scientists have reported cognitive impairment in ApoE
knockout (ApoE-KO) mice (Liu et al., 2013), with cholinergic
deficits (Gordon et al., 1995), decreased synaptic excitability
(Veinbergs et al., 1999), amyloid-β (Aβ) deposition, and
impaired function of synaptosomes (Keller et al., 2000). ApoE-
KO mouse fed with high cholesterol diet would result in
severe atherosclerosis, leakage of blood-brain barrier, neuronal
apoptosis and cognitive impairment (Bink et al., 2013).
Furthermore, scientists have proved that loss of ApoE would lead
to tau phosphorylation increase (Genis et al., 1995; Bi et al., 2001).
Whether tau pathology, like truncated tau and phosphorylated
tau, could aggravate cognitive deficits of ApoE-KO mouse fed
with western type diet was still unknown.
Brain-derived neurotrophic factor (BDNF), as a member of
neurotropic family in nervous system, has various therapeutic
effects via activating tyrosine kinase (TrkB). However, poor
delivery and short half-life in vivo hamper its clinical trials
(Pardridge, 2007). 7,8-dihydroxyflavone (7,8-DHF) is the first
promising small molecular TrkB agonist which fully mimics
the physiological properties of BDNF (Liu et al., 2016). As
a bioavailable chemical, 7,8-DHF can penetrate brain blood
barrier upon intraperitoneal or oral administration to provoke
TrkB and its downstream signaling, such as phosphoinositide
3-kinase/protein kinase B (Akt; Wu et al., 2014), to exert its
central role in pathologic conditions. As a consequence of
activating TrkB, 7,8-DHF inhibits obesity in female mice (Chan
et al., 2015), reduces spine morphology abnormalities in fragile
X syndrome (Tian et al., 2015), enhances axon regeneration
and muscle renovation after peripheral nerves injuries (English
et al., 2013), improves motor function and prolongs survival
in Huntington’s disease (Jiang et al., 2013). Furthermore, it can
reverse synapse loss and prevent memory deficits in Alzheimer’s
disease (AD; Zhang et al., 2014a; Gao et al., 2016).
Glycogen synthase kinase-3β (GSK-3β) is a proline-
directed serine/threonine protein kinase. Its kinases activity
can be inhibited by the phosphorylation of Ser9 through
BDNF/TrkB/AKT pathway. As one of the major tau kinases,
expression of GSK-3β leads to tau hyperphosphorylation at many
sites in vitro (Rankin et al., 2007) and in vivo (Liu et al., 2003),
like ser396 and ser404, the favorite sites for GSK-3β (Liu et al.,
2007). With phosphorylation at ser396 and ser404 by GSK3β, the
pathological conformation of tau becomes tighter and enhances
the aggregation to PHF-tau (phosphorylated tau at ser396
and ser404 epitope). The abnormal tau could be recognized
by monoclonal antibody PHF1 (Jeganathan et al., 2008). Due
to its attractive candidate for modulating AD-like pathology,
researchers have found several small-molecule inhibitors of
GSK-3β to reduce tau pathology, especially tau S396, in vivo
(Selenica et al., 2007). In addition to that, several articles have
demonstrated that by activating AKT, the expression of p-GSK3β
(Ser9) was up-regulated, following with decreased expression
of tau S396 (Jiang et al., 2015; Ren et al., 2015). Furthermore,
scientists have also proved that inhibition of AKT could result
the increased activity of GSK3β correlated with higher expression
of tau S396 and cognitive impairment (Liu et al., 2003). Thus,
we supposed that 7,8-DHF could promote phosphorylation
of GSK3β via AKT/GSK pathway and suppress activation of
GSK-3β to diminish tau Ser396 and PHF1.
Besides hyperphosphorylated tau, Zhang et al. (2014b)
recently showed that the enzyme asparagine endopeptidase
(AEP) cleaved tau at residues 255 and 368 directly. However, the
tau fragment, derived by active-AEP, that does display most of the
toxic effects is tau 1-368. These fragments are toxic independently
of phosphorylation state (Zhang et al., 2014b). AEP, a lysosomal
cystein proteinase, is activated in low PH circumstances and
cleaves protein substrates on the C-terminal side of asparagine
(Rosenmann, 2014). We wonder if levels of active-AEP would
increase in ApoE-KO mice with severe atherosclerosis, and
whether 7,8-DHF could inhibit its pathological influence or not.
Studies have proved that 37-weeks-old male ApoE-KO mouse
fed with low-fat diet did not shown evidence of AD-like
pathology such as amyloid plaques and PHF (Moghadasian et al.,
2001). In our study, male ApoE-knockout mice and C57BL/6
wild-type mice were fed with western type diet with high levels
of cholesterol for 25 weeks and Morris water maze (MWM) tests
were performed at the age of 30 weeks to evaluate behavioral
performances.
In conclusion, in the present study, we investigated 7,8-
DHF potential neuroprotective effects in ApoE-KO mouse by
evaluating the behavioral performances and histological analysis
of hippocampus and cortex. We hypothesized that 7,8-DHF
could alleviate cognitive deficits via activating TrkB and its
downstream signals as well as suppressing activation of AEP.
We also hypothesized that, comparing with C57BL/6 mouse,
ApoE-KO mouse, with severe cerebrovascular atherosclerosis,
expressed more tau pathology, which could aggravate cognitive
impairment.
MATERIALS AND METHODS
Animal
Male ApoE-KO mice and age-matched male C57BL/6 wild-
type controls at 4 weeks of age, weighting 16–18 g, were
purchased from HFK Bioscience Company (Beijing, China). They
were housed under regulated temperature (21–23◦C) with 12 h
light/dark cycle with food and water available. All the mice
were fed separately. This study was implemented conforming
to the Rules of Animal Care and Use Committees of Huazhong
University of Science and Technology with good laboratory
practice and standard operating procedure.
Materials
7,8-DHF was purchased from TCI company (Tokyo, D1916)
and dissolved at 100 mg/ml concentration in 85% saline with
10% dimethylsulfoxide and 5% tweeen-20 (Solarbio, T8220), Akt
(pan; C67E7; #4691), phospho-Akt (Ser473; D9E) XP (#4060),
phospho-GSK-3β (Ser9; 5B3; #9323) were all rabbit monoclonal
antibodies and purchased from Cell Signaling. GSK-3β Rat mAb
(#272536), Legumain/Asparaginyl Endopeptidase (AEP) Sheep
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pAb (AF2058) were purchased from R&D System. Phosphor-Tau
(S396) Rabbit mAb (ab109390), PHF1 Rabbit mAb (ab184951),
BDNF Rabbit mAb (EP1293; ab108383), TrkB Rabbit pAb
(ab33655), and phospho-TrkB Rabbit pAb (Y816; ab75173) were
all purchased from Abcam. Tau N368 rabbit antibody was a gift
from Prof. Ye of Emory University, USA.
Cognitive Impairment of ApoE-KO
Mouse
After 7 days acclimatization period, all mice were fed with
western type diet purchased from HFK Bioscience Company
(Beijing, China, H10141) for 25 weeks. All the mice were
randomly divided into three groups. The first group was normal
group containing 10 C57BL/6 wild-type mice. The second group
was cognitive impairment model group with 10 ApoE-KO mice
in it. The third group was intervention group in which ApoE-
KO mice were treated with 7,8-DHF chronically at the dose of
5 mg/kg (Devi and Ohno, 2012; Zeng et al., 2012; Gao et al., 2016)
daily by oral administration for 25 weeks while the mice in other
two groups were given vehicles daily. During the experiment, all
the mice were measured weight and monitor health status every
week. All experimental researches were conducted at the same
phase during the day.
The Morris Water Maze
After intervention for 25 weeks, MWM tests, which is commonly
thought to be related with hippocampal-dependent spatial
learning and memory (D’Hooge and De Deyn, 2001), were
carried on to assess behavioral performance of ApoE-KO mice
and protective effects of 7,8-DHF on cognitive decline. The
experiment was performed as previously described (Vorhees
and Williams, 2006). A 120 cm diameter tank was filled
with water with non-toxic milk powder dissolved in it. The
pool was divided equally into four quadrants: northeast (NE),
southeast (SE), southwest (SW), and northwest (NW). The
circular platform was 10 cm in diameter located in the center
of NE quadrant, and was submerged 1.5 cm below the surface
of water. Several visual cues were placed in the room as
spatial reference for mice to locate the invisible platform, and
experimenter remained stationary in a fixed location. After
5 days of acquisition trials, the platform was removed and
mice were placed in the SW quadrant, opposite to the former
platform position and the probe trial underwent. During the
whole trials, all mice were maintained on their western type
diet and oral administrated by 7,8-DHF or vehicle. Behavioral
parameters (latency; percentage of time and distance in NE
quadrant; the number of mouse crossing over the position
of the platform) were recorded and evaluated with AVTAS
software.
All the data were analyzed using SPSS to determine the
significance of differences.
Tissue Preparation
Twenty-four hours after behavioral experiment, six mice of
each group were killed by decapitation under anesthesia with
isoflurane. Hippocampus and brain cortex were immediately
dissected on ice and snap frozen in liquid nitrogen, then stored at
−80◦C until used. Four mice from each group were transcardially
perfused with 4% paraformaldehyde and brains were removed
and fixed in 4%PFA at 4◦C.
Western Blotting
Protein preparation was carried out as previously described
(Nie et al., 2015). A total of 42 µg protein of each sample
were electrophoresed on 10% SDS-PAGE, then the protein
samples were transferred to a PVDF membrane (Millipore, USA,
NL1253). The membranes were blocked with 5% milk/PBST for
2 h at room temperature and incubated with a variety of primary
anti-bodies overnight at 4◦C: rabbit monoclonal anti-BDNF
(1:1000, Abcam), rabbit polyclonal anti-TrkB (1:1000, Abcam)
and rabbit polyclonal anti-phospho-TrkB (Y816; 1:1000, Abcam),
rabbit monoclonal anti-Akt (pan; 1:100 0), rabbit monoclonal
anti-phospho-Akt (Ser473; 1:2000), rabbit monoclonal phospho-
GSK-3β (Ser9; 1:1000), GSK-3β Rat mAb (1:2000), Phosphor-
Tau (S396) Rabbit mAb (1:4000), PHF1 Rabbit mAb (1:1000),
Tau N368 rabbit antibody (1:2000), sheep polyclonal anti-
AEP (1:8000). Then, the membranes were washed with TBST
for three times (10 mins/times) and incubated with HRP-
conjugated secondary anti-rabbit antibody (1:4000 for p-AKT,
1:2000 for others) or anti-sheep antibody (1:2000) for 2 h at room
temperature. After washing for three times, the immunoreactive
bands were detected by Bio-Rad imaging system and quantified
via Image J software.
Immunofluorescent Staining
Four brain tissues of each group with formaldehyde solution for
24 h were embedded in paraffin, making pathological section.
The primary antibody is rabbit antibody tau N368 (1:500) for
hippocampus. After all the processes mentioned before (Nie et al.,
2015), fluorescent images of hippocampal were examined on
inversion fluorescence microscope (NIKON DS-U3). Then the
optical density was evaluated via image J software.
Statistic Analysis
Statistical analysis was performed with SPSS Statistics 22.0
software. The significant differences of data were detected with
one- or two-way analysis of variance (ANOVA) followed by LSD.
Data were presented as means ± SEM and the significant level
was set for p< 0.05.
RESULT
7,8-DHF Ameliorates Cognitive
Impairment in ApoE-KO Mice
We performed the MWM to demonstrate whether 7,8-DHF
could rescue deficiency of cognition in ApoE-KO mice or
not. The swimming trajectories of mouse from each group
on the last day of training trails (Figure 1A) and probe trail
(Figure 1B) were shown in Figure 1. Measured by two-way
ANOVA (day∗treatment), the escape latencies of each group
during training trails showed remarkable differences and learning
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FIGURE 1 | (A,B) The swimming trajectory of each group on the last day of training trails (A) and probe trail (B); (C) The statistical analysis of escape latencies in
5 days training trails; (D) Times that the mouse crossed the place where submerged platform was placed were analyzed; In the probe trail, the mouse swimming
times (E) and distances (F) in NE quadrant. Normal, C57BL/6 mouse administrated with vehicles (10%DMSO++5%Tween20+85%saline); ApoE-KO, ApoE-KO
mouse administrated with vehicles (10%DMSO+5%Tween20+85%saline); 7,8-DHF, ApoE-KO mouse administrated with 7,8-DHF. Values were presented as
mean ± SEM. ∗∗p < 0.01, aP < 0.05 versus the ApoE-KO group;bP < 0.01 versus the ApoE-KO group.
was occurring within each group (Figure 1C). Compared with
normal group, ApoE-KO group performed poorly on training
days except for the 1st day (p < 0.01 on the 2nd day and
p < 0.05 on the following days). At the last 2 days of
training trails, 7,8-DHF-treated group showed preference for
the target hidden platform compared with ApoE-KO mouse
(p < 0.01 and p < 0.05, respectively). No significant difference
was found between normal group and 7,8-DHF-treated group
in escaping from the pool. After training trails for 5 days,
the platform was removed and probe trial testing began. We
found out that both the normal group and 7,8-DHF-treated
group crossed over the zone where the hidden platform was
located more frequent than ApoE-KO group (both p < 0.01,
Figure 1D). Furthermore, compared with ApoE-KO group,
larger percentage of swimming distance (Figure 1E) and time
(Figure 1F) in target quadrant were performed in normal group
(p < 0.01) and 7,8-DHF-treated group (p < 0.01). Notably,
both normal group and 7,8-DHF-treated group showed similar
performances in probe trial testing (p > 0.05). Based on
the results above, we proved that long-termed treatment with
7,8-DHF could ameliorate the impairment of spatial learning
and memory in ApoE-KO group and ApoE-KO mice with
western type diet have poorer cognitive level than C57BL/6
mice.
7,8-DHF Affects AKT/GSK3β Mediated
Pathway in ApoE-KO Mice
To investigate whether amelioration of cognitive impairment in
ApoE-KO mice correlated with 7,8-DHF treatment, we assessed
the alteration of BDNF/TrkB/AKT pathway with western blotting
(Figures 2A–D). As we expected, compared with normal group,
chronic long-term administration of 7,8-DHF dramatically up-
regulated the expression of TrkB-phosphorylation (p-TrkB)
and AKT-phosphorylation (p-AKT) in ApoE-KO mice (both
p < 0.05) of hippocampus. GSK3β-phosphorylation protein
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FIGURE 2 | In hippocampus, the western blotting showed that expression of p-TrkB was more in 7,8-DHF-treated group than in normal group (A,B),
so were the downstream pathways involving AKT/GSK3β (C,D). In cortex, AKT/GSK3β also showed significant differences between each group (E–G). ∗p < 0.05,
∗∗p < 0.01. Data were presented as mean ± SEM.
in hippocampus expressed at higher level in the 7,8-DHF-
treated group compared with normal group (p < 0.05) and
ApoE-KO group (p < 0.01). All the three groups expressed
similarly in BDNF. Meanwhile, western blotting further showed
that the expression of p-AKT (p < 0.05; Figures 2E,G) and
p-GSK3β (p < 0.01; Figures 2F,G) in cortex were up-regulated
in 7,8-DHF-treated group compared with ApoE-KO group.
Difference was also found between normal group and 7,8-
DHF-treated group on expression of p-GSK3β (p < 0.05;
Figures 2F,G). Together, the results suggested that in 7,8-
DHF-treated group, significant differences were found in the
expression of p-TrkB, p-AKT, and p-GSK3β, which suggested
that 7,8-DHF might play a role in ameliorate cognitive
impairment in ApoE-KO mice by regulating AKT/GSK3β
pathway.
7,8-DHF Reduces Tau Pathology in
ApoE-KO Mice Via Inhibiting Activation
of GSK-3β and AEP
As mentioned before, 7,8-DHF could inhibit activation of
GSK-3β by activating TrkB/AKT mediated pathway. GSK-3β
phosphorylates tau at individual sites, especially at S396, as its
favorite site. Furthermore, tau phosphorylation is thought to
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take responsibility for accumulation of paired helical filaments
(PHF). So in order to determine the effects of 7,8-DHF on levels
of tau pathology of cognitive impairment ApoE-KO mice, we
evaluated the alteration of abnormal tau by PHF1 antibody,
which can recognize neurofibrillary lesions of brain with higher
affinity for phosphorylation of tau at serine residues 396, and
tau S396 antibody. We found that, compared with ApoE-
KO group (Figures 3A,B), 7,8-DHF-treated group dramatically
down-regulated the expression of tau S396 (p < 0.05) and
PHF1 (p < 0.05) of hippocampus. In cortex (Figures 3G,I),
there were also significant differences between ApoE-KO group
and 7,8-DHF-treated group in PHF1 expression (p < 0.05).
In addition to phosphorylated tau, expression of truncated
tau N368 was also evaluated. As, we all known the pH in
the brain gradually decreases during aging and AEP can be
activated in acid circumstances. The active-AEP fragments tau at
N368 site that elicits tau hyperphosphorylation and aggregation
and provokes neurofibrillary degeneration. But whether the
cognitive impairment of ApoE-KO mice with high-fat diet had
relation with active-AEP and the following truncated tau and
whether 7,8-DHF could decrease tau truncation by inhibiting
activation of AEP were still unknown. Indeed, in hippocampus
(Figures 3C,D), we found significant differences in expression
of active-AEP in both 7,8-DHF-treated group (p < 0.05) and
normal group (p < 0.05) compared with ApoE-KO group.
Meanwhile, we further showed that expression of tau N368
was higher in ApoE-KO group than normal group (p < 0.05)
and 7,8-DHF-treatment can dramatically reduced expression
of tau N368 compared with ApoE-KO group (p < 0.01). In
addition to western blotting, we also found similar result in
immunofluorescence (Figures 3E,F). Brain sections contained
the hippocampus regions were stained with tau N368 to assess
expression of tau pathology. Tau N368 in hippocampal regions
were significantly elevated in the ApoE-KO group compared with
normal group (p < 0.01) and 7,8-DHF-treated group (p < 0.01).
But no statistical significance was found between normal group
and 7,8-DHF-treated group. In brain cortex, the expression of
AEP and tau N368 were also assessed (Figures 3H,I). Active-
AEP was remarkably expressed at high levels in ApoE-KO group
compared with both normal group (p < 0.01) and 7,8-DHF-
treated group (p < 0.01). But lower expression of active-AEP
was found in normal group than in 7,8-DHF-treated group
(P < 0.01). The lowest expression of tau N368 was found in
normal group (p< 0.05), but no significant difference was found
between ApoE-KO group and 7,8-DHF-treated group. Taken
together, the results indicated that consistent with the result
of behavioral test, 7,8-DHF might play a role in ameliorating
cognitive impairment by decreasing expression of active-AEP
and its following truncated tau N368 of hippocampus. But in
cortex, although with dramatic decrease in expression of AEP,
7,8-DHF failed to down-regulated expression of tau N368. It
is noteworthy that both in cortex and hippocampus, ApoE-
KO mice with high-fat diet expressed dramatic high levels
in active-AEP and tau N368 that matched its poor cognitive
condition. These results indicated that, the cognitive impairment
of ApoE-KO might be associated with tau phosphorylation and
truncation and the abnormal pathology of tau could be reduced
by 7,8-DHF-induced neuroprotection via inhibiting activation of
GSK-3β and AEP.
DISCUSSION
In our present study, we demonstrated that memory-
deteriorating of 30-weeks old ApoE-KO mice with western
type diet might be associated with higher expression of truncated
tau N368 as well as active-AEP in both brain cortex and
hippocampus compared with C57BL/6 mice at the same age,
whereas, the phosphorylated tau S396 might not play a vital
role in impairing cognitive function. We found that cognitive
impairment could be reversed with long-term administration
of 7,8-DHF, a TrkB receptor agonist, which could activate
AKT/GSK3β signaling pathway as well as suppress expression of
active-AEP, and then display its remarkable protective effects by
decreasing production of tau N368 and phosphorylated tau at
serine 396.
The underlying mechanisms of cerebrovascular disease
risk factors, like atherosclerosis and hyperlipidemia, affecting
cognition are poorly understood. ApoE-KO mice fed with high
cholesterol diet resulted in severe atherosclerosis, increased
leakage of blood-brain barrier, neuronal apoptosis, and cognitive
impairment (Bink et al., 2013). Nowadays, vascular dysfunction
seems to be closely related with AD-like pathological changes
composed of Aβ and tau, the main components of plaques
and tangles, respectively (Di Marco et al., 2015). ApoE has
three isoforms-ε2 allele, ε3 allele, and ε4 allele, which plays
an important role in nervous system via modulating Aβ
metabolism. Many researches have reported the relationship
between pathology of AD and ApoE genotype (DeMattos et al.,
2004; Jiang et al., 2008; Kim et al., 2009; Morris et al., 2010;
Liu et al., 2013; Poirier et al., 2014). The ApoE4 isoform,
which is regarded as genetic risk factor of AD, exhibited poor
ability in regulating Aβ clearance, therefore Aβ aggregation
accelerated in the brain which boosted age-dependent cognitive
impairment while the other two isoforms promoted effective
removal of Aβ peptides from brain and reduced the risk of
cognitive decline (Jiang et al., 2008; Liu et al., 2013). ApoE
efficiently stimulates degradation of Aβ within the brain (Jiang
et al., 2008). In addition to that, scientists have proved the
increasing accumulation and deposition of Aβ in the absence
of ApoE in vivo (DeMattos et al., 2004) and in vitro (Jiang
et al., 2008), which were in line with cognitive impairment of
this kind of mouse. Furthermore, potential AD-like mechanisms
such as tau pathology, which might contribute to cognitive
deficits in ApoE-KO mice (Oitzl et al., 1997), has not been
ruled out (Bi et al., 2001). Our behavioral examination proved
that 30-weeks old ApoE-KO mouse with western type diet
for 25 weeks exhibited poor spatial learning and memory
compared with C57BL/6 mouse with the same age and same
diet. Consistent with poor performance of ApoE-KO mouse in
MWM tests, AEP, which might be activate by acid PH, and its
downstream truncated tau N368 were significantly increased in
both cortex and hippocampus which indicated that tau N368
may mediate cognitive dysfunction in ApoE deficiency mouse.
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FIGURE 3 | Western blotting showed expression of tau S396 and PHF1 in hippocampus and the statistical analysis (A,B). In addition to that, expression
of active-AEP and tau N368 of each group in hippocampus were also analysis (C,D). Immunofluorescent staining further reconfirmed the findings that ApoE-KO
mouse expressed more tau N368 in hippocampus than C57BL/6 mosue, while 7,8-DHF decrease the expression of tau N368 compared with ApoE-KO mouse
(E,F); In cortex, expression of PHF1, active-AEP, and tau N368 were showed by western blotting (G,H), and significant differences were found between groups (I).
∗p < 0.05, ∗∗p < 0.01. Data were presented as mean ± SEM. Scale bar = 50 µm.
Interestingly, although some researches have proved expression
of phosphorylated tau in ApoE-KO mouse, in our study, no
significant difference was found in tau S396 between ApoE-KO
mouse and C57BL/6 mouse, which suggested that tau S396 might
not play a major role in alteration of cognition of ApoE-KO
mouse at age of 30 weeks. Because antibody PHF1 have higher
affinity in detecting tau peptides containing phosphorylated
Ser396 and Ser404 than other tau pathology, it is understandable
both ApoE-KO group and C57BL/6 group express similarly in
PHF1.
Scientists have proved that administration of 7,8-DHF as a
potent way to prevent or even rescue cognitive impairment
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in various diseases via multiple neuroprotective molecular
mechanisms in both vivo and vitro. It preserved integration
of synapses and synaptic plasticity (Zeng et al., 2012), protects
neurons from toxicity of β-amyloidogenesis as well as reduces
expression of BACE1 in five familial AD mutation mouse model
of AD (Devi and Ohno, 2012). It could also ameliorate spatial
memory deficits via increasing synapse protein level of AMPA
subunits even in the absence of attenuating expression of amyloid
precursor protein or Aβ in the Tg2576 AD mouse model
(Gao et al., 2016). Besides AD-associated memory impairment,
7,8-DHF could also reverse memory deficits in schizophrenia
(Yang et al., 2014), Fragile x syndrome (Tian et al., 2015),
scopolamine-induced memory dysfunction (Chen et al., 2014),
and age-related cognitive impairment (Zeng et al., 2012). But
whether it could ameliorate cognitive deficits in ApoE-KO mice
was still unknown. We have proved that cognitive decline of
ApoE-KO mice might be obviously ameliorated with long-
term administration of 7,8-DHF. We demonstrated that chronic
treatment with 7,8-DHF significantly diminished expression of
tau S396, PHF1, and tau N368 by inhibiting activation of GSK3β
and reducing expression of active-AEP alternatively.
In Summary, our study indicated that cognitive deficit of
ApoE-KO mice with western type diet might associated with
truncated tau N368 due to the activation of AEP. Long-term
treatment of 7,8-DHF could ameliorate cognitive impairment
by inhibiting expression of tau pathology, which suggested
a potential therapeutic strategy for 7,8-DHF in treating tau-
related cognitive impairment. But how did 7,8-DHF acted on the
activation of AEP deserve further study.
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